Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-402 for VTE Prophylaxis After Total Knee Replacement
NCT00793234Phase 2Completed
- Sponsor
- Oxurion
- Start
- Dec 2008
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of vunacizumab in venous thromboembolism (VTE) (4 arms), sponsored by Oxurion. Primary endpoints: Occurrence of total bleeding (major and/or clinically relevant non-major) and Composite of asymptomatic DVT and symptomatic VTE. Started Dec 2008; status: completed.
02
Drugs
vunacizumab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00793234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793234.